Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ptc Therapeutics (PTCT) Gross Margin (2016 - 2025)

Ptc Therapeutics (PTCT) has 10 years of Gross Margin data on record, last reported at 95.78% in Q4 2025.

  • For Q4 2025, Gross Margin rose 342.0% year-over-year to 95.78%; the TTM value through Dec 2025 reached 98.45%, up 1245.0%, while the annual FY2025 figure was 97.28%, 440.0% up from the prior year.
  • Gross Margin reached 95.78% in Q4 2025 per PTCT's latest filing, down from 98.91% in the prior quarter.
  • Across five years, Gross Margin topped out at 107.39% in Q2 2024 and bottomed at 90.52% in Q4 2023.
  • Average Gross Margin over 5 years is 94.74%, with a median of 93.87% recorded in 2021.
  • Peak YoY movement for Gross Margin: crashed -298bps in 2023, then surged 1334bps in 2024.
  • A 5-year view of Gross Margin shows it stood at 94.36% in 2021, then fell by -1bps to 93.49% in 2022, then decreased by -3bps to 90.52% in 2023, then grew by 2bps to 92.36% in 2024, then increased by 4bps to 95.78% in 2025.
  • Per Business Quant database, its latest 3 readings for Gross Margin were 95.78% in Q4 2025, 98.91% in Q1 2025, and 92.36% in Q4 2024.